Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 160 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H... May 3, 2024 Breaking: Longtime Broadcast Journalist Cokie Roberts Dies At 75 September 17, 2019 Dad Creates Inclusive Children’s Book For Daughter With Disability And Others... January 25, 2022 Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with... December 18, 2023 Load more HOT NEWS FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... New on NCI Websites for December 2018 Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... Studying “Total Diet” and Its Impact on Health, Including Cancer Risk
